[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-stages-3b-5\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-stages-3b-5":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100651072","effect-of-daprodustat-and-epoetin-alpha-on-anemia-in-patients-not-undergoing-dialysis-100651072",false,"NCT07755683","Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis","Inclusion Criteria:\n\n1. Age 18-65 years, either gender.\n2. Confirmed CKD stage 3, 4, or 5.\n3. Not currently receiving dialysis at time of screening.\n4. Hemoglobin at presentation: 8.0-10 g\u002FdL, serum ferritin \\> 100 ng\u002FmL at screening and transferrin saturation (TSAT) \\> 20% at screening.\n\nExclusion Criteria:\n\n1. Clinically significant gastrointestinal bleeding, major surgery or RBCs transfusion in last 4 weeks\n2. Pregnant, breast-feeding, not agreed to use contraception\n3. Uncontrolled hypertension (\\>180\u002F100 mmHg).\n4. Recent major cardiovascular event including acute coronary syndrome or stroke, or in the past 3 months, chronic liver disease (ALT OR AST \\> 40 IU, hepatitis B or C)\n5. Use of any experimental\u002Finvestigational drug within 30 days of screening or know hypersensitivity against trial drugs\n6. Active or high risk malignancy or treatment for malignancy with in the past 2 years.\n7. Uncorrected iron deficiency despite iron supplementations.\n8. Acute sepsis as evident by increase C-reactive protein (CRP), Total leukocyte count (TLC).","ALL","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Anemia in CKD patients is mainly attributed to impaired kidney being unable to adequately respond to hypoxia and\u002For anaemia by inducing erythropoietin (EPO) production iron disorders, blood loss, shortened erythrocyte survival time and inflammation. High mortality among patients with advanced renal failure is directly related to the severity of anemia and hypoalbuminemia, particularly within the first six months.4, 5 Currently, the main treatment modalities for anemia in CKD include injections of erythropoiesis stimulating agents (ESAs), iron supplementation, and blood transfusion. EPO resistance and iron refractory anemia require red blood cell transfusions.\n\nThe rationale of this study is to compare the effectiveness of daprodustat versus epoetin alpha on hemoglobin level in patients with chronic kidney disease not on hemodialysis. Literature showed that epoetin alpha has better effectiveness in improving hemoglobin level and curing anemia in CKD patients. But conflicting results have been osbevred showing no difference in both drugs. In routine, both drugs are recommended for anemia in non-dialysis CKD patients. This trial is planned to check the effect of Daprodustat in patients not undergoing dialysis is primarily to provide an effective, orally administered alternative to current injectable anemia treatments, which are associated with several limitations and safety concerns. The treatment strategies and effectiveness optimization for patients with chronic kidney disease complicated by anemia remain a key issue that urgently needs to be addressed.",[26,27],"Chronic Kidney Disease (Stages 3b-5)","Anemia Associated With Chronic Kidney Disease",[29,30,31],"Anemia","Daprodustat","Epoetin Alpha","NOT_YET_RECRUITING","2026-08-04",{"date":35,"type":36},"2026-08-10","ACTUAL",{"date":38,"type":20},"2026-09-01",{"date":40,"type":20},"2027-02-28",{"name":42,"class":43},"Services Hospital, Lahore","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100612748","left-atrial-appendage-occlusion-in-dialysis-patients-with-atrial-fibrillation-a-multicentre-pilot-study-100612748","NCT07257614","Left Atrial Appendage Occlusion in Dialysis Patients With Atrial Fibrillation: A Multicentre Pilot Study","LAAO-DAF","Inclusion Criteria:\n\n* Age \\>=18\n* End stage renal failure on peritoneal dialysis or haemodialysis\n* documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation;\n* CHADS2-VASc \\>=2\n* The patient is willing and able to comply with the required medication post-procedure and follow-up evaluations;\n* Able to consent\n\nExclusion Criteria:\n\n* Patients who require long-term anticoagulation for a condition other than AF, e.g. pulmonary embolism, deep vein thrombosis, anti-phospholipid syndrome\n* Mechanical valve replacement\n* Active infection with bacteraemia;\n* Pregnant or nursing patients and those who plan pregnancy during the study period. Female patients of childbearing potential must have a negative pregnancy\n* Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, any device material or component (nickel titanium, PET, polypropylene), and\u002For contrast;\n* Left atrial appendage is obliterated and surgical ligated;\n* Underwent any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to the procedure or planned to have the interventional or surgical procedure within 60 days after implant procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, etc.);\n* Recent (within 90 days prior to procedure) stroke, transient ischemic attack, or myocardial infarction;\n* New York Heart Association Class IV;\n* Life expectancy is less than 1 year;\n* Current participation in another investigational drug or device study.\n* Echocardiogram exclusion:\n\n  i. Moderate mitral stenosis or above ii. LVEF \\\u003C30% iii. Intracardiac thrombus iv. Presence of a cardiac tumour. v. Existing circumferential pericardial effusion \\>5 mm; vi. Presence of a high-risk Patent Foramen Ovale (PFO), defined as an atrial septal aneurysm (excursion \\>15 mm or length \\>15 mm) or large shunt (early, within 3 beats and\u002For substantial passage of 20 bubbles)",{"count":53,"type":20},40,"1 Year","OBSERVATIONAL","Objectives: This pilot study aims to evaluate the safety and efficacy of left atrial appendage occlusion (LAAO) in dialysis patients and atrial fibrillation (AF) to establish a novel stroke prevention strategy and determine an optimal post-occlusion antithrombotic regime. Page 3 of 50 Hypothesis: The study tests the hypotheses that LAAO is safe for dialysis patients, that a single antiplatelet regimen postprocedure is safe, and that LAAO effectively reduces the composite endpoint of stroke\u002Ftransient ischemic attack and major bleeding compared to standard care. Instruments: The study employs a multicenter, single-arm prospective registry design. Eligible participants, aged ≥18 with documented AF and ESRF on peritoneal dialysis (PD) or hemodialysis (HD), will undergo LAAO using the Watchman Flx PRO device. Propensity score matched historical cohort from dialysis registry will be identified for comparison.\n\nMain Outcome Measures: The primary endpoint is the composite of stroke\u002Ftransient ischemic attack\u002Fsystemic embolism and non-procedural-related major bleeding at one year. Secondary endpoints include individual rates of these events, procedural safety and device occlusion effectiveness. Data Analysis and Expected Results: Statistical analysis will involve descriptive statistics, chi-squared tests, and propensity score matching. A p-value of \\\u003C0.05 will be deemed significant. The pilot study anticipates a low peri-procedural complication rate (≤5%) and confirms LAAO's efficacy in stroke and major bleeding reduction in Chinese PD and HD patients compared to standard care. This data will inform the design of a larger randomized controlled trial aimed at validating LAAO as a safe alternative for AF management in dialysis populations.",[58,26,59,60,61,62],"Dialysis","Atrial Fibrillation","End Stage Kidney Failure","Stroke Prevention in Patients With Atrial Fibrillation","Left Atrial Appendage Occlusion","2025-12-02",{"date":65,"type":36},"2025-12-04",{"date":67,"type":20},"2026-01-05",{"date":69,"type":20},"2028-07-05",{"name":71,"class":72},"Prince of Wales Hospital, Shatin, Hong Kong","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":5},"100585407","monitoring-hyperkalemia-using-point-of-care-ai-enabled-ecg-device-among-patients-with-chronic-kidney-disease-stages-3b-5-100585407","NCT06901960","Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5","Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5 to Reduce Rate of Hyperkalemia - a Practical Randomized Clinical Trial","POCKET","Inclusion Criteria:\n\n* Patients with chronic kidney disease stages 3b-5 (eGFR: 10 - \\\u003C45 ml\u002Fmin\u002F1.73m²)\n* Patients with regular visits in the study sites to manage their chronic kidney disease (≥ 1 visit per 3 months during the past year before enrollment)\n* Willingness to participate in the study with signed informed consent\n\nExclusion Criteria:\n\n* Patients already under kidney replacement therapy or will receive kidney replacement therapy in 6 months\n* Unwillingness or without the ability to monitor hyperkalemia using the study device\n* Patients with heart pacemaker implanted","99 Years",{"count":83,"type":20},1066,[23],"The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to optimal management of hyperkalemia (the reduced occurrence of serum potassium ≥ 5.0 mmol\u002FL during 6 months of follow-up). It will also learn about the adherence of using a mobile monitoring device.\n\nParticipants will:\n\n* Measure their serum potassium using an AI-enhanced point-of-care ECG device at least twice per week\n* Receive health education prompts to reduce intake of potassium rich foods if their electrocardiogram device measured serum potassium is abnormal\n* Receive alerts to visit nephrology clinic if their electrocardiogram device measured serum potassium is continuously abnormal",[26],[88,89,90],"Chronic kidney disease","hyperkalemia","ECG","RECRUITING","2025-09-11",{"date":94,"type":36},"2025-09-17",{"date":96,"type":36},"2025-04-02",{"date":98,"type":20},"2026-12-31",{"name":100,"class":72},"Peking University First Hospital"]